DW
Therapeutic Areas
Quanterix Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Neurology Panel (Nf-L, GFAP, tau) | Neurodegenerative Diseases (Alzheimer's, Parkinson's, MS, TBI) | Commercial/IVD Development |
| SARS-CoV-2 Serology Test | COVID-19 Immunity | Commercial (IVD) |
| Oncology Assays (e.g., HER2, PSA) | Cancer Detection & Monitoring | Commercial (RUO) |
| Cytokine Assays | Immunology & Inflammation | Commercial (RUO) |
| Aβ42/40 Ratio Assay | Alzheimer's Disease Pathology | Commercial (RUO) |
Leadership Team at Quanterix
MT
Masoud Toloue
Chief Executive Officer
MA
Michael A. Doyle
Chairman of the Board
BJ
Brian J. Blaser
Director
KC
Kevin C. Hrusovsky
Founder, former Executive Chairman & CEO
AN
Amir Nashat
Director
WP
William P. Donnelly
Chief Financial Officer
EM
Eliot M. Lurier
Chief Operating Officer
MD
Michael D. Elftman
Chief Commercial Officer
MR
Michael R. Millett
Senior Vice President, General Counsel & Secretary
VS
Vandana Sriram
Vice President, Business Development